NASD
| Health Care |
Biotechnology
Cyclacel Pharmaceuticals, Inc. (CYCC)
LAST (4 Apr)
Extended HOURS (00:00 PM ET)
MARKET CAP
VOLUME
| Open | 0.22 |
| Previous Close | 0.23 |
| Day Range | 0.20 - 0.23 |
| 52-Week Range | 0.20 - 4.00 |
| All-Time High | 2,142,000.00 |
| Avg. Volume (50-day) | 341,119.88 |
| EPS (TTM) | -5.3278 |
| Next Earnings Date | 2025-05-15 (AMC) |
| Last Earnings Date | 2025-04-02 |
| Forward Annual Dividend (Yield) | - |
| Trailing Annual Dividend (Yield) | - |
| Options | No |
| P/E Ratio | -0.0400 |
| PEG Ratio | - |
| Price to Book | -0.94 |
| Price to Cash Flow | - |
| Price to Free Cash Flow | - |
| Total Sales (TTM) | 0.04 M |
| Revenue per Share (TTM) | 0.00 |
| Shares Outstanding | 207.336 M |
| Share Float (%) | 205.34 M |
| % Held by Institutions | 0.34 |
| Dividends Per Share (TTM) | - |
| Ex-Dividend Date | - |
| +/- EMA(20) | 0.29 (-26.21%) |
| +/- SMA(50) | 0.32 (-33.13%) |
| +/- SMA(200) | 0.79 (-72.91%) |
| 5-Day Perf. | -28.43% |
| 1-Month Perf. | -34.56% |
| 3-Month Perf. | -53.48% |
| 6-Month Perf. | -76.57% |
| YTD Perf. | -43.09% |
| 1-Year Perf. | -90.24% |
| RSI(14) | 24.23 |
| ATR(14) | 0.03 |
| ADX(14) | 28.76 |
| Beta (5Y) | 0.90 |
FOR STOCKCHARTS MEMBERS ONLY
Unlock earnings and revenue history when you join StockCharts
As a StockCharts Member, you can review earnings results and analyze revenue and earnings growth over time. Bring a balance of technicals and fundamentals to your approach when you join today!
CYCC
Cyclacel Pharmaceuticals, Inc.
Sector: Health Care
Industry: Biotechnology
Employees:
Description
Cyclacel Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the provision of cell cycle, transcriptional regulation and DNA damage response biology to develop medicines for cancer and other proliferative diseases. It operates through the United States and United Kingdom geographical segments. The company builds a biopharmaceutical business, which is focused on hematology and oncology based on a pipeline of novel drug candidates. Its products include CYC065, seliciclib, and sapacitabine. The company was founded by Ronald J. Berenson, David Philip Lane, and David Glover on August 13, 1996 and is headquartered in Berkeley Heights, NJ.
CYCC has triggered the following predefined scans:
| P&F Double Bottom Breakdown |
| P&F Descending Triple Bottom Breakdown |
| Moved Below Lower Price Channel |
| New 52-week Lows |
FOR STOCKCHARTS MEMBERS ONLY
Unlock custom technical alerts when you join StockCharts
As a StockCharts Member, you can create your own unique alerts with the technical criteria that matters most to you. Stay ahead of important moves and never miss a thing in the markets.
FOR STOCKCHARTS MEMBERS ONLY
Unlock ChartLists to save and organize your charts when you join StockCharts
As a StockCharts Member, you can save the charts you're watching to your own account with ChartLists. Accessible from any device, you can organize, review and analyze your charts on-the-go, anytime, anywhere.
